... after admission ( p < 0.05). Conclusion: According to the characteristic of undetermined onset time window of WUIS, more WUIS patients would be benefited from the rt-PA intravenous thrombolytic treatment when it is conducted under the guidance of rapid MRI. Recombinant tissue plasminogen activator...

... Institute of Health Stroke Scale Score (NIHSS), modified Rankin scale (mRS) on admission and discharge, risk factors, stroke characteristics and thrombolysis complications. Recombinant tissue plasminogen activator (rtPA) doses relative to body weight and blood volume were also assessed. In a separate...

... agent most frequently administered (n = 19; 73.1%), whereas streptokinase and recombinant tissue plasminogen activator were used in 2 cases each (7.7%). Intracranial hemorrhages occurred in 3 cases (11.5%). Extracranial hemorrhages occurred in 5 cases (19.2%), and overall there were 3 cases of serious...

... recombinant tissue plasminogen activator (rt-PA) at any of the 19 participating hospitals from January 1, 2008 till December 31, 2010. Treatment groups were those actually treated by IV rt-PA in 0–3 h and those treated by IV rt-PA in 3–4.5 h. Duration from symptom onset to arrival in the emergency department...

... to July 2011 by cross-referencing the following MeSH terms: ‘thrombolysis’, ‘recombinant tissue plasminogen activator’, ‘rtPA’, ‘hemorrhagic stroke’, ‘cerebral hemorrhage’, ‘hematoma’ and ‘ischemic stroke’. Demographic information, baseline National Institute of Health Stroke Scale (NIHSS) scores, time...

.... Recombinant tissue plasminogen activator Alteplase Octogenarians Combined intravenous/intra-arterial approach Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is effective in acute ischaemic stroke patients treated within 4.5 h of symptom onset [ 1,2 ]. However, evidence supporting...

...N. Galldiks; O. Zaro-Weber; C. Dohmen; M. Neveling; W.F. Haupt; G.R. Fink; J. Sobesky Background: While the application of intravenous systemic thrombolysis (IVT) with rt-PA (recombinant tissue plasminogen activator) in older patients is currently moving into the focus of epidemiological studies...

... for an estimation of an overall treatment effect in an analysis combining infarct size and mortality. Spontaneous death occurred in: 45% of the animals in the control group, 41% in the group treated with tirilazad alone, 38% of the animals treated with recombinant tissue plasminogen activator (rt-PA) and 25...

... echo T 2 *-weighted images after intravenous recombinant tissue plasminogen activator (rt-PA) administration. Methods: We included 43 consecutive patients with anterior-circulation ischemia who underwent MRI studies before and after thrombolysis. Each hemorrhage was classified as a hemorrhagic...

...Christine Sølling; Niels Hjort; Mahmoud Ashkanian; Leif Østergaard; Grethe Andersen Introduction: The use of MRI may alter the target population for intravenous recombinant tissue plasminogen activator (rtPA) treatment relative to conventional CT. If selection changes, it remains crucial...

...Yang-Ha Hwang; Jong-Geun Seo; Ho-Won Lee; Sung-Pa Park; Chung-Kyu Suh Background: The aim of this study was to examine the rate of early neurological deterioration (END) and favorable outcomes after acute lacunar stroke following the use of intravenous recombinant tissue plasminogen activator (IV...

... effect of recombinant tissue plasminogen activator (rtPA) on autoregulation dynamics in this situation. Methods: We studied 16 patients with acute middle cerebral artery (MCA) occlusion and rtPA thrombolysis (intra-arterial or intravenous application, or both). Controls were 71 healthy adults and 11...

... with acute BA occlusion, treated with intra-arterial recombinant tissue plasminogen activator, a high number of acute ischaemic lesions, based on diffusion-weighted imaging, is a predictor of poor clinical outcome. 24 07 2007 7 11 2007 15 5 2008 © 2008 S. Karger AG, Basel 2008...

... intervals of prognostic significance, the functional forms of this predictive relationship should be found and compared for recombinant tissue plasminogen activator (rt-PA)- and placebo-treated patients of the first European Cooperative Acute Stroke Study. Methods: We studied the 615 patients with acute...

...M.R. Walters; K.W. Muir; J. Harbison; K.R. Lees; G.A. Ford Objective: To present the preliminary experience of implementing intravenous thrombolytic therapy for acute ischaemic stroke in three UK stroke centres. Background: Recombinant tissue plasminogen activator for ischaemic stroke received...

... injected a new ray of optimism in the pessimistic outlook normally associated with stroke [ 5 ]. Authors proposed administering thrombolysis consisting of intravenous treatment with recombinant tissue plasminogen activator (r-TPA) within 3 h of the onset of symptoms [ 6, 7 ]. That was the protocol...

...Takenori Yamaguchi; Tohru Hayakawa; Haruhiko Kiuchi We report the results of a double-blind, placebo-controlled, multicenter trial on the efficacy of intravenous recombinant tissue plasminogen activator (rt-PA, duteplase) in 98 patients with hyperacute thromboembolic stroke (<6 h) of the carotid...